NCM · Biotechnology

TCRT (TCRT) Stock

$1.89 -0.31% NCM: TCRT Healthcare

Valuation

MetricValue
Price$1.89
Market Cap$4.63M
P/E Ratio-1.09
P/B Ratio2.03
P/S Ratio1897.87
EPS (TTM)$-2.20
52-Week High$6.20
52-Week Low$1.67
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-1.98%
ROA-92.31%
ROCE-200.00%
Gross Margin-63.33%
Operating Margin-1381.67%
Net Margin-1369.67%
Debt/Equity0.00
Current Ratio2.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$3.0M$0$0$0
Operating Profit$-78.0M$-35.0M$-34.0M$-5.0M$-4.0M
Net Profit$-79.0M$-38.0M$-35.0M$-5.0M$-4.0M
EPS$-53.80$-25.97$-21.97$-2.92$-2.20
Op Margin-19484.7%-1201.4%-685340.0%-48120.0%-84500.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$95.0M$65.0M$8.0M$3.0M$3.0M
Total Liabilities$37.0M$26.0M$2.0M$1.0M$1.0M
Cash$76.0M$39.0M$6.0M$1.0M$1.0M
Borrowings$30.0M$20.0M$0$0$0

Latest News

Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study GlobeNewswire · Jun 29, 2026 Alaunos Reports Positive Preclinical Obesity Drug Results Across Weight, Liver, Insulin Markers Stocktwits · May 26, 2026 Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies GlobeNewswire · May 26, 2026 Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models GlobeNewswire · May 18, 2026 Ziopharm: Q1 Earnings Snapshot Associated Press · May 15, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-61.0M$-29.0M$-30.0M$-5.0M$-3.0M
Investing Cash Flow$-7.0M$0$1.0M$0$0
Financing Cash Flow$1.0M$0$0$0$0
Net Cash Flow$-39.0M$-23.0M$-47.0M$-5.0M$0
Free Cash Flow$-65.0M$-29.0M$-30.0M$-5.0M$-3.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-56.66%
Quick Ratio1.63
Interest Coverage—
Return 1Y-36.98%
Return 3Y-96.98%
Return 5Y-99.40%

Ownership

Insiders Held14.51%
Institutions Held6.53%
Institutions Float Held7.64%
Institutional HolderSharesReport Date
Blackrock Inc.21,3532026-03-31
Geode Capital Management, LLC22,5602026-03-31
Vanguard Fiduciary Trust Co15,4972026-03-31
Vanguard Capital Management LLC14,0632026-03-31
HRT Financial LP13,3272026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADXNAddex Therapeutics Ltd $5.89 -0.17% -0.72 $4.24M 0.00%
AIM $0.24 -5.84% -0.09 $801193 0.00%
CYCN $3.57 +0.28% -2.99 $16.71M 0.00%
IBO $0.43 -2.27% -1.61 $5.38M 0.00%
KTTA $0.45 -2.17% -0.25 $3.35M 0.00%

About TCRT

TCRT is led by CEO Holger Weis, employs 1 people, headquartered in US, publicly traded since 2005.

TCRT stock trades at $1.89 with a market capitalization of $4.63M. The stock is valued at a price-to-earnings (P/E) ratio of -1.09, price-to-book of 2.03, price-to-sales of 1897.87. Over the past 52 weeks the stock has ranged between $1.67 and $6.20, and currently trades 69.5% below its 52-week high.

On profitability, TCRT generates a return on equity (ROE) of -1.98%, return on capital employed of -200.00%, an operating margin of -1381.67%, a net profit margin of -1369.67%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides